La valutazione non invasiva delle Epatopatie Biliari Autoimmuni
|
|
- Arline Pope
- 6 years ago
- Views:
Transcription
1 La valutazione non invasiva delle Epatopatie Biliari Autoimmuni Marco Carbone, MD, PhD Divisione di Gastroenterologia Università di Milano Bicocca Milano UOC Gastroenterologia Ospedale Universitario San Gerardo ASST Monza
2 Conflict of interest statement COMPANY NAME Intercept Pharma Gilead Tobira therapeutics Menarini RELATIONSHIP Consultant, Advisory Board, Travel grant Investigator, travel grant Investigator Travel grant
3 PBC PSC
4 Disease course of cholestatic liver diseases Intact bile ducts
5 PBC
6 Primary Biliary Cirrhosis Cholangitis Definition Chronic, cholestatic liver disease characterized by non suppurative granulomatous cholangitis; duct destruction and ductopenia, and portal fibrosis that progresses slowly to biliary cirrhosis. Putative autoimmune patogenesis Diagnosis AMA and PBC specific ANA in a patient with otherwise unexplained elevation of ALP is diagnostic of PBC. A liver biopsy is not essential for the diagnosis of PBC, except for seronegative PBC. Disease course: The rate of disease progression in PBC is highly variable; majority have indolent disease. Therapy: UDCA first line (20 40% non response) OCA second line (FDA & EMA approval)
7 Flow chart of management of PBC Grading & Staging 1 year YES Assessment of high- vs low-risk patients 20-40% NO Biopsy? EASL CPG J Hepatol 2017
8 PBC is an heterogeneous disease Premature ductopenic variant Portal hypertensivetype Fastprogressors UDCA nonresponse PBC AIH overlap Hepatocellular failure type
9 Unmet needs in PBC CHALLENGES IN PROGNOSIS Biomarkers for high risk disease at diagnosis Predictive markers of response to UDCA CHALLENGES IN CARE DELIVERY Implementation of stratification criteria in practice enabling identification of high risk patients Management location and approach for low risk patients CHALLENGES IN TRIAL DESIGN Consensus stratification protocols to select high risk patients for second line therapy trials Surrogate markers of outcome as endpoints acceptable to regulatory bodies Dyson J et al. J Hepatol 2015
10 Current needs for non invasive tests in PBC Diagnosis: AMA M2 highly specific Disease activity: Alk Phos well established (enough?) Fibrosis: preliminary data on ELF and elastography Ductopenia: no markers proposed Treatment response: Alk Phos & bilirubin dismal marker Outcome: ALP and bilirubin
11 Liver biopsy in PBC Features Portal inflammation Ductopenia Copper associated proteins Interface hepatitis Limitations sampling error Inter observer variation
12 Standard serum liver tests
13 Prediction of survival Treatment response criteria Criteria Definition No patients Evaluation time point c statistics at 5, 10, or 15 years * Barcelona, 2006 >40% decrease of ALP or normalization year 0.56, 0.61, 0.61 Paris I, 2008 ALP<3xULN, AST<2xULN and bilirubin 1mg/dL year 0.81, 0.81, 0.80 Rotterdam, 2009 Normalization of abnormal bilirubin and/or albumin year NA Toronto, 2010 ALP 1.67xULN 69 2 year 0.65, 0.70, 0.70 Paris II, 2011 ALP 1.5xULN, AST 1.5xULN and bilirubin 1mg/dL year 0.75, 0.75, 0.74 Ehim, % decrease of GGT months NA * c-statistics calculated in the UK-PBC Research Cohort.
14 Treatment response criteria UDCA response is a strong predictor of long term survival Carbone M, Mells GF et al. Gastroenterology 2013
15 Continous risk scores Fitted lines derived from the best fitting multivariable fractional polynomial model UK PBC cohort Cubic spline function GLOBE cohort Hazard ratio Hazard ratio Hazard ratio ALP x ULN after 12 months of UDCA Transaminases x ULN after 12 months of UDCA Bilirubin x ULN after 12 months of UDCA Hazard ratio Hazard ratio Albumin x LLN Platelet count x LLN Carbone M, et al. Hepatology 2016 Lammers et al. Gastroenterology 2014
16 The UK PBC Risk Score Algorithm = 1 baseline survival function^exp( *(alp12 xuln ) * (((altast12xuln/10)^ 1) ) *(ln(bil12xuln/10) ) *(albxlln ) *(pltxlln )) Baseline survivor function: (at 5 years); (at 10 years); (at 15 years) Carbone M et al. Hepatology 2016
17 The PBC Risk Scores Tool for disease management to identify high risk patients for closer monitoring and second line therapies, as well as low risk patients who require infrequent monitoring and might even be followed up in primary care. Stratification of patients in clinical trials Surrogate endpoint measure in clinical trials
18 Response guided approach Elastography Gp-210 YES UK-PBC risk score Globe score 20-40% NO Biopsy
19 Response guided approach Elastography Gp-210 YES UK-PBC risk score Globe score 20-40% NO Biopsy
20
21 Baseline prediction of treatment response to UDCA AIM Identification of BASELINE variables predicting likelihood of UDCA response and model development METHODS Study population: 3062 (UK) patients who received UDCA within 1 2 years from the diagnosis Endpoints: UDCA response (defined as ALP<1.67 x ULN); Entire cohort used for model derivation & cross validation External validation (Italian cohort=450)
22 Probability of UDCA response ALP BILIRUBIN Manuscript submitted
23 Probability of UDCA response AGE Manuscript submitted
24 Probability of UDCA response ALT Manuscript submitted
25 Model of UDCA response Variable (variable scale) Parameter Estimate Standard error Wald statistic p-value Intercept ALP (IU/L) * (Log scale) Bilirubin (umol/l) * (Inverse square root scale) TA (IU/L) * (Log scale) Age (years) (Original scale) Interval Diagnosis-UDCA start (years) (Original scale) ALP delta (IU/L) Original scale < < < < Manuscript submitted
26 Model of UDCA response Probab ility level Event Correct Incorrect Percentage Event Nonevent Nonevent Correct Sensitiv ity Specific ity False POS False NEG Manuscript submitted
27 Ductular reaction and intermediate hepatocytes predict treatment failure (n=20) With the permission of G. Carpino, V. Cardinale, Gaudio E, Alvaro D. Sapienza University, Rome Manuscript submitted
28 Response guided approach Elastography Gp-210 YES 20-40% NO UK-PBC risk score Globe score Biopsy?
29 Baseline risk guided approach Elastography UDCA treatment Gp-210 failure score YES 20-40% NO UK-PBC risk score Globe score Biopsy?
30 Serological profile
31 AMA M2 no prognostic value Carbone M, Mells GF et al. Gastro 2013 Lammers W et al. Gastro 2014 Anti gp210 6 fold risk of progression to liver failure/transplantation Wesierska Gadek & Invernizzi P et al. Hepatology 2006 Nakamura et al. Hepatology 2007 Anti centromere antibodies associate with PH Nakamura et al. Hepatology 2007
32 Anti gp210 and anti centromere Wesierska Gadek & Invernizzi P et al. Hepatology 2006 Nakamura et al. Hepatology 2007
33 Disease trajectories based on antibody profile The Japan Society of Hepatology. Hepatol Research 2007
34 Markers of fibrosis
35 Transient elastography N=150, single center and UDCA treated Corpechot C. Hepatol 2012
36 Transient elastography N=150, single center and UDCA treated Corpechot C. Hepatol 2012
37 Transient elastography Corpechot C. Hepatol 2012
38 Transient elastography Corpechot C. Hepatol 2012
39 Transient elastography No external validation yet Unclear whether adds predictive value to biochemical response Neglect presence of cholestasis, ductopenia, interface hepatitis
40 Enhanced Liver Fibrosis (ELF) Study cohort=161 Multicenter national data extrapolated from a clinical trial of MTX+UDCA AUROC 0.76 AUROC 0.75 Mayo M. Hepatol 2008
41 Enhanced Liver Fibrosis (ELF) Mayo M. Hepatol 2008
42 Enhanced Liver Fibrosis (ELF) Unclear whether adds predictive value to biochemical response to UDCA Unclear impact of longitudinal stability vs. fluctuation over time No external validation yet Marker of disease severity or stage?
43 AST/platelet ratio index Derivation cohort=386 (UK); Validation cohorts: 479 (Germany) and 150 (Canada) Trivedi P. Gut 2016
44 AST/platelet ratio index Elevated APRI is associated with future risk of adverse events, independently and additively of UDCA response Possible future surrogate endpoint in clinical trials in PBC
45
46 PSC
47 Primary Sclerosing Cholangitis PSC is a challenging illness that is characterised by chronic bile duct destruction and progression to end stage liver disease Incidence varies geographically (1.3 x 100,000 in Northern Europe ) 80% men, median age % of cases in northern European populations are associated with inflammatory bowel disease Unknown pathogenesis No effective medical treatments are available Consistent risk of developing colangioca and Colorettal Ca
48 Proposed pathway of PSC management Trivedi P et al. Hepatology 2015
49 Current needs for non invasive tests in PSC Diagnosis: MRI cholangiography +/- biopsy Disease activity: no markers accepted, imaging required Cancer screening: no markers accepted Outcome: lacking
50 Standard serum liver tests
51
52 Can Biochemical Surrogates Be Extrapolated to PSC? ALP based biochemical response criteria Does PSC biochemical responders in clinical trials mean improved survival?
53 Amsterdam prognostic model Derivation cohort (Amsterdam)=692; validation (Oxford)=264 Model: PSC subtype, age at diagnosis, albumin, platelets, aspartate aminotransferase, alkaline phosphatase and bilirubin C statistics=0.64 De Vries E. Gut 2017
54 Markers of fibrosis
55 Transient elastography Single center cohort=167 (France) Corpechot et al. Gastro 2014
56 Transient elastography Neglect impact of cholestasis/cholangitis, IBD activity External validation pending (FICUS ongoing) Corpechot et al. Gastro 2014
57 Enhanced Liver Fibrosis (ELF) Derivation cohort=167; Validation cohorts: 138 (Norway) Vesterhus M et al. Hepatology 2015
58 Enhanced Liver Fibrosis (ELF) ELF cannot be benchmarked disease affection is even more patchy than in PBC, and it is probable that the performance of the ELF test may surpass liver biopsy Internal validation but short disease duration in LTfree survivors (<5 years) Impact of longitudinal stability vs. fluctuations not clear Stratifier of disease severity vs. stage? Vesterhus M et al. Hepatology 2015
59 Serological profile
60 Autoantibodies ANCA low sensitivity and specificity Positive correlation between serum levels of anticardiolipin antibody and disease severity measured by MRS and histologic stage of disease was shown
61 Serum IgG4 Between 9% and 15% of PSC patients have raised serum IgG4 Unclear impact on survival IgG4 >1.4 and <2.8 g/l, IgG4/IgG1 ratio with a cutoff at 0.24 is correlate to IgG4 colangiopathy Stratifying properties of serum IgG4 in PSC remain unsubstantiated and require further evaluation Boonstra K et al. Hepatology 2014 Mendes F et al. Am J Gastro 2006 Benito de Valle et al. DLD 2014
62 Future potential stratifiers
63 Genome wide time to event analysis (N=1600) SNPs at 6 loci achieved P DISCOVERY < Of these, none identified in GWAS of susceptibility of PBC Deviation in the tail of the distribution is suggestive of true associations CHR SNP A1 EST SE P-value Genes 7p22 rs G MAD1L1,MIR4655,FTSJ2,NUDT1,SNX8 7q31 rs G NRCAM,PNPLA8,RPL7P32,THAP5,DNAJB9 8p22 rs A SGCZ 8q21.3 rs A SOX5P,LOC ,DCAF4L2,MMP16 11p15.5 rs G INS-IGF2,IGF2, MIR483,IGF2-AS,INS,TH,MIR q22-23 rs34580 A Intergenic Mells GF & Carbone M Unpublished data
64 Metabolomics Bell et al. Liver Int 2015
65 Serum micrornas as novel biomarkers for PSC and CCA PSC CCA Bernuzzi F, Invernizzi et al. Clin Exp Immunol 2016
66 Summary A stratified management of PBC and PSC represents a major unmet clinical need in hepatology Development/improvement of (non invasive) markers is needed in PBC and PSC for the assessment of: stage of disease treatment response disease progression/outcome The rise of data intensive biology, advances in information technology and the availability of large scale cohort offer a unique opportunity for developing a stratified medicine in the field
67 Grazie CENTRO MALATTIE AUTOIMMUNI DEL FEGATO Pietro INVERNIZZI Francesca BERNUZZI Federica MALINVERNO Vincenzo RONCA Marta GEMMA Alessio GERUSSI Laura CRISTOFERI Giulia BONATO George F MELLS Richard R SANDFORD Steven FLACK Lynda SMITH Dave E JONES UK PBC Consortium Abenavoli L Almasio P Alvaro D Andreone P Andriulli A Azzaroli F Baiocchi L Battezzati PM Bollani S Calvaruso V Cardinale V Colleredo G Coco B Colombo Crocè L Donato M Fabris L Floreani A Frugiuele Galli A Giannini E Labbadia G Lleo A Marra F Marzioni M Mattalia A Miele L Missale G Morisco F Muratori L Portincasa P Picciotto A Rigamonti C Rosina F Spinzi G Toniutto P Valenti L Zuin M
68
69 Active and recently run clinical trials in PBC Carbone M, Mells GF et al. Dig Liv Dis IN PRESS
70
71 PBC is an heterogeneous disease Variant syndromes Autoantibody profile Symptom profile PBC AIH overlap syndrome may be found in ~10% and the premature ductopenic variant in ~5% of cases Anti centromere antibodies (ACA) are found in ~30%, anti sp100 antibodies in ~20 30% and anti gp210 antibodies in ~10% of cases Pruritus is present in 40% and fatigue is present in 45% of cases Modes of disease progression Rate of disease progression The biochemical response to UDCA Portal hypertensive type versus hepatocellular failure type progression Ranging from no overt progression at one end of the spectrum, to ESLD occurring within a few years of diagnosis, at the other Variable; it strongly predicts the long term outcome.
72 Clinical scenarios showing the effect of the transaminasis on the chance to respond to UDCA therapy based on the ALP and total bilirubin levels. Recipient age ALP ratio Bilirubin ratio Ta ratio Delta ALP ratio Diag- UDCA time Estimated probability of responese 95% C.I (0.92, 0.96) (0.94, 0.96) (0.95, 0.97) (0.95, 0.98) (0.96, 0.98) (0.65, 0.76) (0.72, 0.79) (0.67, 0.82) (0.79, 0.85) (0.79, 0.87) (0.58, 0.73) (0.66, 0.75) (0.72, (0.74, 0.82) (0.75, 0.84) (0.52, 0.70) (0.60, 0.73) (0.66, 0.77) (0.69, 0.80) (0.70, 0.82) (0.72, 0.83) Manuscript submitted
73 Ductopenic variant
74 Primary Biliary Cholangitis
75 Challenges in PBC Treatment in high risk patients (beyond UDCA) PRESENT: non responder to UDCA as 1 st line therapy FUTURE: more proactive, don t waste liver & bile duct time, aim at LFTs normalisation, choleretic as backbone Young female with premature ductopenic variant Male patients with HCC (even despite UDCA response) Patients with advanced fibrosis and risk of disease progression Optimize treatment (in non responders) Now several therapeutic stategies will be available Opportunities for combination (FXR + PPAR?) How to bring all of this into clinical reality by efficient trial strategy Classic playground for P5 medicine
76 External validation of the UK PBC Risk Score China (N=223) Switzerland (N=501) Poster FRI-379
77 Dynamic risk prediction in PBC Bilirubin 12 (log-scale) Delta ALP after treatment Poster SAT-377
78 The PBC Risk Scores Algorithm = 1 baseline survival function^exp( *(alp12 xuln ) * (((altast12xuln/10)^ 1) ) *(ln(bil12xuln/10) ) *(albxlln ) *(pltxlln )) Baseline survivor function: (at 5 years); (at 10 years); (at 15 years) Tool for disease management to identify high risk patients for closer monitoring and second line therapies, as well as low risk patients who require infrequent monitoring and might even be followed up in primary care. Stratification of patients in clinical trials Surrogate endpoint measure in clinical trials
79 Cholangiographic Stratification Annual three dimensional MRC to score liver parenchymal appearances, PH and bile duct lesions predicted radiological progression from baseline with high accuracy (AUROC, >0.8) Ruiz A et al. Hepatology 2014 Dominant strictures natural history data are restricted to specialist centers, with reduced survival Small duct PSC disease progression is relatively infrequent, occurring over a longer time period reflecting difficulties in CCA recognition
80 EASL CPG J Hepatol 2017
81 Interaction between ALT * Bilirubin on survival Unpublished data
Towards Precision Medicine in Primary Biliary Cholangitis
Riunione Monotematica A.I.S.F. 2016 THE FUTURE OF LIVER DISEASES: Beyond HCV is there a role for the hepatologist? 14 th October 2016 Towards Precision Medicine in Primary Biliary Cholangitis Marco Carbone,
More informationRisk stratification in PBC
Risk stratification in PBC Christophe Corpechot Reference Center for Inflammatory Biliary Diseases Saint-Antoine hospital, Paris, France What is currently known (background) PBC : chronic, progressive
More informationDiagnosis and Management of PBC
Diagnosis and Management of PBC Cynthia Levy, MD, FAASLD University of Miami Miller School of Medicine Miami, Florida 1 Primary Biliary Cholangitis (PBC) Chronic cholestatic liver disease Autoimmune in
More informationPBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
More informationACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationNew insights in pathogenesis and therapy of primary biliary cholangitis. Keith D. Lindor Dean Professor of Medicine
New insights in pathogenesis and therapy of primary biliary cholangitis Keith D. Lindor Dean Professor of Medicine OUTLINE PBC Epidemiology Diagnosis Treatment Incidence of PBC and PSC Trends Boonstra
More informationCurrent Concepts in the Management and Treatment of PBC & PSC
Current Concepts in the Management and Treatment of PBC & PSC Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London A family affair? Central vein Hepatocytes
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk PBC for Healthcare Practitioners Introduction
More informationOverview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN
Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN 2012 Annual Conference PSC Partners Seeking a Cure May 5, 2012 Primary Sclerosing Cholangitis Multifocal
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationA Review of Liver Function Tests. James Gray Gastroenterology Vancouver
A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationKa-Shing Cheung, MBBS, MPH 1, Wai-Kay Seto, MD 1,2, James Fung, MD 1,2, Ching-Lung Lai, MD 1,2 and Man-Fung Yuen, MD, PhD 1,2
Citation: (2017) 8, e100; doi:10.1038/ctg.2017.23 Official journal of the American College of Gastroenterology www.nature.com/ctg Prognostic Factors for Transplant-Free Survival and Validation of Prognostic
More informationAutoimmune and cholestatic liver diseases
Autoimmune and cholestatic liver diseases Prof. Tom Hemming Karlsen Research Institute of Internal Medicine & Department of Transplantation Medicine University of Oslo & Oslo University Hospital, Norway
More informationChronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths
Chronic Biliary Disease Dr Susan Davies & Dr Bill Griffiths Chronic Biliary Disease Terminology is confusing with pathologists and hepatologists using the same language BUT with different meanings. Chronic
More informationOcaliva (obeticholic acid tablets)
Ocaliva (obeticholic acid tablets) Policy Number: 5.01.619 Last Review: 11/2018 Origination: 11/2016 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationPrimary biliary cirrhosis (PBC) and primary sclerosing
Risk Stratification in Autoimmune Cholestatic Liver Diseases: Opportunities for Clinicians and Trialists Palak J. Trivedi, 1 Christophe Corpechot, 2 Albert Pares, 3 and Gideon M. Hirschfield 1 Primary
More informationAESOP Overview and Inclusion/Exclusion Criteria Richard Pencek, PhD
747-207 AESOP Overview and Inclusion/ Criteria Richard Pencek, PhD Sr Director, Clinical Research, Intercept Pharmaceuticals, Inc. 2 PSC Forum 2 AESOP: A Phase 2 Randomized, Placebo-Controlled Trial, Dose-Finding
More information21/07/2017. Update on Autoimmune Biliary Disease. Changing Role of Liver Biopsy in PBC and PSC. Primary Biliary Cirrhosis Cholangitis
Primary Biliary Cirrhosis Cholangitis Update on Autoimmune Biliary Disease Changing Change in Nomenclature for PBC : From Cirrhosis to Cholangitis (EASL Panel, Beuers et al J Hepatol Nov 2015, Gut Nov
More informationFat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationImproving the Lives of Patients with Liver Diseases
Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and
More informationACCME/Disclosures. PBC and PSC Revisited 4/6/2016. Primary Biliary Cirrhosis Cholangitis (PBC)
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationChronic Cholestatic Liver Diseases
Chronic Cholestatic Liver Diseases - EASL Clinical Practice Guidelines - Rome, 8 October 2010 Ulrich Beuers Department of Gastroenterology and Hepatology Tytgat Institute of Liver and Intestinal Research
More informationProgram Disclosure. This activity is supported by an educational grant from Intercept Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership
More informationPrimary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants
Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic
More informationHangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam
Clinical Aspects of Primary Biliary Cirrhosis Hangzhou, 15 March 2008 Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Epidemiology of Primary
More informationAutoimmune Liver Diseases
2nd Pannonia Congress of pathology Hepato-biliary pathology Autoimmune Liver Diseases Vera Ferlan Marolt Institute of pathology, Medical faculty, University of Ljubljana Slovenia Siofok, Hungary, May 2012
More informationPBC features and management in the era of UDCA and Budesonide
PBC features and management in the era of UDCA and Budesonide Raoul Poupon, MD Université P&M Curie, AP-Hôpitaux de Paris, Inserm, Paris, France The changing pattern of PBC Over the last 2 decades: More
More informationIn primary biliary cholangitis (PBC), progression
HEPATOLOGY COMMUNICATIONS, VOL. 2, NO. 6, 2018 Clinical Application of the GLOBE and United Kingdom-Primary Biliary Cholangitis Risk Scores in a Trial Cohort of Patients With Primary Biliary Cholangitis
More informationPrimary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS
Primary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS Nikolaos T. Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD Associate Professor and Chief, Division of Gastroenterology and Hepatology
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationUpdate on Autoimmune Liver Disease. Role of Liver Biopsy in Autoimmune Hepatitis, PBC and PSC
Update on Autoimmune Liver Disease Role of Liver Biopsy in Autoimmune Hepatitis, PBC and PSC Stefan Hübscher, School of Cancer Sciences, University of Birmingham Dept of Cellular Pathology, Queen Elizabeth
More informationNoncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis
Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids Cholestasis Biochemical hallmark Impaired bile flow from liver to small intestine Alkaline phosphatase is primary
More informationHépatopathies auto-immunes
16 ème Journée d'automne Lausanne, le 19 octobre 2017 Hépatopathies auto-immunes Nurullah Aslan et Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationPediatric PSC A children s tale
Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;
More informationTHE BRITISH SOCIETY OF GASTROENTEROLOGY/UK-PBC PRIMARY BILIARY CHOLANGITIS TREATMENT AND MANAGEMENT GUIDELINES
THE BRITISH SOCIETY OF GASTROENTEROLOGY/UK-PBC PRIMARY BILIARY CHOLANGITIS TREATMENT AND MANAGEMENT GUIDELINES AUTHORS: HIRSCHFIELD GM, DYSON JK, ALEXANDER GJ, CHAPMAN M, COLLIER J, HUBSCHER S, PATANWALA
More informationCholestatic Liver Diseases: Update on Diagnosis and Management. Cholestatic Liver Diseases: Location of Injury Determines Phenotype
Cholestatic Liver Diseases: Update on Diagnosis and Management R. Todd Stravitz, M.D. Hume-Lee Transplant Center Section of Hepatology Virginia Commonwealth University Cholestatic Liver Diseases: Location
More informationPBC treatment: the present and future. Maggie Bassendine Professor of Hepatology
PBC treatment: the present and future Maggie Bassendine Professor of Hepatology Primary biliary cirrhosis 20-25yrs OLT/ Death Symptoms: Fatigue, itching, jaundice Autoimmune disease: Focal small bile duct
More informationOverview of PSC Making the Diagnosis
Overview of PSC Making the Diagnosis Tamar Taddei, MD Assistant Professor of Medicine Yale University School of Medicine Overview Definition Epidemiology Diagnosis Modes of presentation Associated diseases
More informationDomenico ALVARO, MD Sapienza, University of Rome, Italy. Congresso Nazionale della Società Italiana di GastroReumatologia, Roma, 25 Giugno 2015.
Epatite autoimmune e sindrome da "overlap Domenico ALVARO, MD Sapienza, University of Rome, Italy Congresso Nazionale della Società Italiana di GastroReumatologia, Roma, 25 Giugno 2015. AUTOIMMUNE HEPATITIS
More informationColangitis Esclerosante Primaria: Manejo Clínico y Endoscópico
Colangitis Esclerosante Primaria: Manejo Clínico y Endoscópico Andrés Cárdenas, MD, MMSc, PhD, AGAF, FAASLD GI / Liver Unit, Hospital Clinic Institut de Malalties Digestives i Metaboliques Associate Professor
More informationObeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks Draft Background and Scope Background: April 21, 2016 Primary biliary cholangitis
More informationWhy to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?
Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationKey Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto
Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis
More informationBiliary tract diseases of the liver
Biliary tract diseases of the liver Digestive Diseases Course Bucharest 2016 Rob Goldin r.goldin@imperial.ac.uk How important are biliary tract diseases? Hepatology 2011 53(5):1608-17 Approximately 16%
More informationPrimary Sclerosing Cholangitis Medical Management
Primary Sclerosing Cholangitis Medical Management Kapil Chopra M.D. Assistant Professor of Medicine Division of Transplant Medicine Mayo Clinic Arizona PSC Primary sclerosing cholangitis is a progressive
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationAutoimmune hepatitis
Autoimmune hepatitis: Autoimmune hepatitis a spectrum within a spectrum Alastair Burt Professor of Pathology and Dean of Clinical Medicine Newcastle University Spectrum of autoimmune liver disease Autoimmune
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationValue of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1355 1360 Value of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease PIOTR MILKIEWICZ,*, HAYMAN BUWANESWARAN,* CATALINA
More informationPatologia sistematica V Gastroenterologia Prof. Stefano Fiorucci Autoimmune liver diseases
Patologia sistematica V Gastroenterologia Prof. Stefano Fiorucci Autoimmune liver diseases Harrison s Principles of Internal Medicine 18-19 Ed. 2012 e seguenti Chronic hepatitis classification by cause
More informationGEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE
GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE Kalliopi Azariadis 1, Nikolaos K. Gatselis 1, Kalliopi Zachou 1, Vasiliki Lygoura 1, Pinelopi Arvaniti 1, Eirini I. Rigopoulou 1, Georgia
More informationTABLE OF CONTENTS SYMPOSIUM AGENDA. Diagnosis, Stratification of Risk, and Initial Treatment in PBC
PBC Novel Pathways for Treatment of Cholestatic Liver Disease TABLE OF CONTENTS Faculty Biographies SYMPOSIUM AGENDA Introduction Kris V. Kowdley, MD Diagnosis, Stratification of Risk, and Initial Treatment
More informationBiomarkers of PSC. Steve Helmke, Ph.D.
Biomarkers of PSC Steve Helmke, Ph.D. steve.helmke@ucdenver.edu Biomarkers of PSC Currently Used in Clinical Practice Biomarkers Used in Prognostic Models of PSC Wiesner et al, 1989 Age Bilirubin Biopsy
More informationSingle Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785
Single Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785 Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ocaliva (obeticholic acid) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ocaliva (obeticholic acid) Prime Therapeutics will review Prior Authorization
More informationPrimary biliary cirrhosis (PBC) is an autoimmune
Early Biochemical Response to Ursodeoxycholic Acid and Long-Term Prognosis of Primary Biliary Cirrhosis: Results of a 14-Year Cohort Study Li-Na Zhang, 1,2 * Tian-Yan Shi, 1,2 * Xu-Hua Shi, 1,2 Li Wang,
More informationLIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA
LIVER SPECIALTY CONFERENCE USCAP 2016 Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA Nothing to disclose Case History 47-year-old male, long standing ileal
More informationApproach to the cholestatic patient
Approach to the cholestatic patient Tom Hemming Karlsen Oslo University Hospital, Norway ASSA SAGES, August 8th, 2015 Best of EASL is a program supported by an unrestricted medical education grant by Merck
More informationTratamiento endoscópico de la CEP. En quien como y cuando?
Tratamiento endoscópico de la CEP. En quien como y cuando? Andrés Cárdenas, MD, MMSc, PhD, AGAF, FAASLD GI / Liver Unit, Hospital Clinic Institut de Malalties Digestives i Metaboliques University of Barcelona
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Case 1 52 year-old woman, referred for liver blood tests
More informationSarah Landes October 23, 2014
Sarah Landes October 23, 2014 A T-cell mediated inflammatory destruction of intralobular bile ducts progressively leading to cholestasis and cirrhosis 9:1 F to M ratio Mostly diagnosed between 30-60 years
More informationPrototypes of autoimmune hepatitis and sclerosing cholangitis in childhood
RIUNIONE MONOTEMATICA AISF 2013 Personalizzazione della Cura in Epatologia 17-19 ottobre 2013, PISA Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood La sottoscritta dichiara di
More informationIn 1993, the International Autoimmune Hepatitis Group
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:417 421 Validation and Modification of Simplified Diagnostic Criteria for Autoimmune Hepatitis in Children ELIZABETH MILETI,* PHILIP ROSENTHAL,*, and MARION
More informationInterface hepatitis in PBC: Prognostic marker and therapeutic target
Interface hepatitis in PBC: Prognostic marker and therapeutic target Raoul Poupon Service d Hépatologie, Hôpital Saint-Antoine, Paris Faculté de Médecine Pierre & Marie Curie, Paris Key features of
More informationInvasive. Sampling error. Interobserver variability. Nondynamic evaluation of
How to assess liver fibrosis Serum markers or FibroScan vs. liver biopsy? Laurent CASTERA & Pierre BEDOSSA Hôpital Beaujon, AP-HP, Clichy Université Paris-VII France 4 th Paris Hepatitis Conference, Paris,
More informationACG Clinical Guideline: Primary Sclerosing Cholangitis
ACG Clinical Guideline: Primary Sclerosing Cholangitis Keith D. Lindor, MD, FACG 1, Kris V. Kowdley, MD, FACG 2, and M. Edwyn Harrison, MD 3 1 College of Health Solutions, Arizona State University, Phoenix,
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of
More informationWhat s new in Hepatology AASLD 2016
What s new in Hepatology AASLD 2016 CWN Spearman C Kassianides What s new in Hepatology? AASLD 2016 CWN SPEARMAN Hepatitis C Alcoholic liver disease Cholestatic Liver Disease Primary biliary Cholangitis
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationThe Norwegian PSC Research Center Biobank
The Norwegian PSC Research Center Biobank Trine Folseraas Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Medicine and Transplantation, Oslo University
More informationShifting Paradigms in Primary Biliary Cholangitis A CE/CME Activity
Overview Shifting Paradigms in Primary Biliary Cholangitis A CE/CME Activity In this video series, Kris Kowdley, MD, and Seth Sclair, MD, share insight into changes in the management of patients with primary
More informationLFTs: an update A MacGilchrist PLIG meeting 31st January 2019
LFTs: an update A MacGilchrist PLIG meeting 31 st January 2019 LFTs: what are we trying to achieve? (1) The case against investigation abnormal LFTs in up to 21% of the population only 1-2% develop significant
More informationDhanpat Jain Yale University School of Medicine, New Haven, CT
Dhanpat Jain Yale University School of Medicine, New Haven, CT Case history 15 years old female presented with fatigue. Found to have features suggestive of cirrhosis with esophageal varices, splenomegaly
More informationCIRROSI E IPERTENSIONE PORTALE NELLA DONNA
Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di
More informationEfficacy and Safety of Seladelpar in Primary Biliary Cholangitis 52-Week Analysis of a Dose-Ranging Phase 2 Study
Efficacy and Safety of Seladelpar in Primary Biliary Cholangitis 52-Week Analysis of a Dose-Ranging Phase 2 Study Bowlus CL, Neff G, Aspinall R, Galambos M, Goel A, Hirschfield G, Kremer AE, Mayo MJ, Swain
More informationObeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks Evidence Report July 26, 2016 Institute for Clinical and Economic
More informationAspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis
The Turkish Journal of Pediatrics 2015; 57: 492-497 Original Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis Aysel Ünlüsoy-Aksu 1,
More informationPresentation and mortality of primary biliary cirrhosis in older patients
Age and Ageing 2000; 29: 305 309 Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET
More informationAutoimmune Hepatitis. Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern. November 14th, 2018
Autoimmune Hepatitis Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern November 14th, 2018 AIH - Definition Manns MP J Hepatol 2015, vol 62, P 100-111 AIH - Definition Autoimmune hepatitis (AIH) is
More informationUpdate on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics
More informationChronic Cholestatic Liver Disease
1 Cholestasis - Definition Biochemical Chronic Cholestatic Liver Disease Defect in bile secretory mechanisms leading to accumulation in blood of substances normally excreted in bile. In some conditions
More informationQuantitative Assessment of the Liver: Breath Tests. M. Shadab Siddiqui, M.D. Virginia Commonwealth University
Quantitative Assessment of the Liver: Breath Tests M. Shadab Siddiqui, M.D. Virginia Commonwealth University Objectives Principles of breath tests Breath tests in NAFLD Potential applications of breath
More informationHow the concept of biochemical response influenced the management of primary biliary cholangitis over time
ORIGINAL ARTICLE How the concept of biochemical response influenced the management of primary biliary cholangitis over time W.J. Lammers 1 *, M. Leeman 1, C.I.J. Ponsioen 2, K. Boonstra 2, K.J. van Erpecum
More informationTransient elastography in chronic viral liver diseases
4 th AISF POST-MEETING COURSE Roma, 26 Febbraio 2011 Transient elastography in chronic viral liver diseases CRISTINA RIGAMONTI, M.D., Ph.D. Transient elastography (TE): a rapid, non-invasive technique
More informationIdiopathic adulthood ductopenia manifesting as jaundice in a young male
Idiopathic adulthood ductopenia manifesting as jaundice in a young male Deepak Jain*,1, H. K. Aggarwal 1, Avinash Rao 1, Shaveta Dahiya 1, Promil Jain 2 1 Department of Medicine, Pt. B.D. Sharma University
More informationInterpreting Your Tests
Interpreting Your Tests Lisa M. Forman, MD, MSCE Associate Professor of Medicine Section Hepatology and Liver Transplantation University of Colorado Denver Outline Bile Duct Anatomy Lab Tests LFTs Tumor
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function
More informationAlkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis
246 Hilscher M, et al., 2016; 15 (2): 246-253 ORIGINAL ARTICLE March-April, Vol. 15 No. 2, 2016: 246-253 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for
More informationLaboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland
Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland Sanjiv Chopra, MD, MACP Professor of Medicine Harvard Medical School Editor In Chief Hepatology Section Up To Date Serum
More informationNoninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD
Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis
More informationA Case of Autoimmune Hepatitis with Antimitochondrial Antibody and No Detectable Antinuclear Antibody
FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF St. Marianna Med. J. Case Report Vol. 32, pp. 33 38, 2004 FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF A Case
More informationPBC and PSC: Back to Basics
Disclosure No financial interest or other relationship with the manufacturer(s) of the product(s) or provider(s) of the service(s) that will be discussed in this presentation. PBC and PSC: Back to Basics
More informationResident, PGY1 David Geffen School of Medicine at UCLA. Los Angeles Society of Pathology Resident and Fellow Symposium 2013
Resident, PGY1 David Geffen School of Medicine at UCLA Los Angeles Society of Pathology Resident and Fellow Symposium 2013 85 year old female with past medical history including paroxysmal atrial fibrillation,
More informationWhere a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy Lammers, Willem J; Hirschfield, Gideon; Corpechot, Christophe;
More informationPREVALENCE OF NAFLD & NASH
- - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)
More informationNon-Invasive Testing for Liver Fibrosis
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview
More informationCITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS
CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS Interpreting abnormal liver function tests (LFTs) and trying to diagnose any underlying liver disease is a common scenario in Primary
More informationTwo Cases of Primary Sclerosing Cholangitis Overlapping with Autoimmune Hepatitis in Adults
CASE REPORT Two Cases of Primary Sclerosing Cholangitis Overlapping with Autoimmune Hepatitis in Adults Go Igarashi 1, Tetsu Endo 1, Kenichiro Mikami 1, Naoya Sawada 1,RyuSatake 1, Rie Ohta 1, Juichi Sakamoto
More information